by Annie De Groot | Oct 2, 2018 | News, Thinking Out Loud -Blog
Revolutionizing Risk Assessment: Generic Peptide Drugs and Their Impurities EpiVax has been awarded a $1 million contract from the Food and Drug Administration (FDA) to demonstrate and validate the best practices and procedures for assessing generic peptide drugs and...
by Sarah Moniz | Jun 13, 2018 | Featured, News
NEW YORK CITY AND PROVIDENCE, RI., June 12, 2018 (BUSINESS WIRE) — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced the closing of a $1.2M Bridge Financing. The investors include NextWaveBio, Morningside Venture Investments, Accelerate...
by Admin Epivax | Feb 3, 2017 | Events, Featured
Update: This event has been cancelled by the organizers. Thank you for your interest. As an expert in immunogenicity screening, EpiVax’s CEO/CSO, Dr. Annie De Groot, will be conducting a training on state of the art methods of in silico and in vitro analysis to...
by Annie De Groot | Jul 8, 2014 | Featured, News
New Immunogenicity Analysis Tool Emerges from Dartmouth-EpiVax-URI Collaboration “In Silico” Host Cell Protein for Protein Therapeutics Providence, RI. Tuesday, July 8th, 2014 A Public-private partnership resulted in the development of a new web-based tool that will...
